MORF Morphic Holding Inc

Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced its participation at investor conferences during the month of March.

3/6/249:10 AM ETGI/Microbiome Panel Discussion at the TD Cowen 44th Annual Health Care Conference

10:30 AM ETFireside Chat at the TD Cowen 44th Annual Health Care Conference

3/13/24Jefferies Biotech on the Bay SummitandLeerink Partners 2024 Global Biopharma Conference

A live webcast of the panel discussion and fireside chat at the TD Cowen 44th Annual Health Care Conference will be available on the Investor section of Morphic’s website at www.morphictx.com. An archived replay will be available on the company’s website following the conference.

About Morphic TherapeuticMorphic Therapeutic is a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer. Morphic is also advancing its pipeline and discovery activities in collaboration with Schrödinger using its proprietary MInT technology platform which leverages the Company’s unique understanding of integrin structure and biology. For more information, visit www.morphictx.com.

ContactsMorphic TherapeuticChris Erdmanchris.erdman@morphictx.com617.686.1718